Sanofi with We Are ILL, Inc. Rings the Opening Bell
About This EventSanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the ...
Nasdaq13d
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of chlamydia infection. The company plans to begin a phase I/II study soon ...
Nasdaq13d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple ...
Nasdaq6d
Sanofi with We Are ILL, Inc. Rings the Nasdaq Stock Market Opening Bell
Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in ...
Nasdaq13d
FDA Grants Fast Track Designation To Sanofi's MRNA Vaccine Candidate For Chlamydia Prevention
Sanofi said it is planning a phase 1/2 randomized ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
Nasdaq20d
Goldman Sachs Initiates Coverage of Sanofi - Depositary Receipt () (SNY) with Neutral Recommendation
Fintel reports that on March 21, 2025, Goldman Sachs initiated coverage of Sanofi - Depositary Receipt () (NasdaqGS:SNY) with a Neutral recommendation. As of March 19, 2025, the average one-year ...
Nasdaq14d
Sanofi's Tolebrutinib Under FDA Priority Review For Treating NrSPMS & Slowing Disability Progression
Sanofi noted that Tolebrutinib is currently ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...
Nasdaq6d
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent ...
Q1 Earnings Forecast for Sanofi Issued By Leerink Partnrs
Stock analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for Sanofi in a report released on ...
Nasdaq4d
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
Nurix Therapeutics NRIX shares rose 8.7% on Wednesday after the company announced that Sanofi SNY has in-licensed exclusive rights to an undisclosed Nurix program aimed at a previously ...